View printer-friendly version << Back
MEDNAX Announces Acquisition of Perinatology Practice in Texas

Expands Continuum of Women's and Newborn Care in Houston Market

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Oct. 20, 2014-- MEDNAX, Inc., (NYSE: MD) today announced the acquisition of Houston Perinatal Associates, P.A., a private physician group practice based in Houston, Texas. The practice will become part of MEDNAX’s Pediatrix Medical Group division.

Established in 1994, Houston Perinatal Associates consists of four physicians and 30 other clinical and administrative staff who provide comprehensive high-risk maternal-fetal medicine services at The Woman’s Hospital of Texas and 10 satellite perinatal clinics. The practice provides services including obstetrics and delivery, ultrasounds, prenatal diagnosis, medical and surgical complications of pregnancy, as well as the management of multiple gestations. In addition, the practice provides maternal-fetal medicine services to three Houston metropolitan area hospitals and one surgery center, as well as telemedicine services to patients in Lufkin, Texas.

This acquisition extends MEDNAX’s ability to provide a continuum of care in the Houston market, including neonatal, perinatal, pediatric cardiology, pediatric hospitalist and anesthesia services. It also enhances the services MEDNAX provides at The Woman’s Hospital of Texas, which include perinatal care, neonatal care at the hospital's Level II and Level III neonatal intensive care units, pediatric cardiology and, through MEDNAX's American Anesthesiology division, anesthesia services.

“As a physician-led national medical group, MEDNAX will allow us to maintain our clinical autonomy while supporting the growth of our practice and improving office efficiencies in a changing healthcare environment,” said Brian Kirshon, M.D., who will serve as medical director for the practice. “We look forward to collaborating with clinicians across the country on high-risk maternal-fetal care, and to being part of the research, education and quality initiatives that are the foundation of the company.”

The practice was acquired for cash and the transaction is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

With this acquisition, eight physician group practices have become part of MEDNAX in 2014, two as part of Pediatrix Medical Group and six as part of American Anesthesiology.


MEDNAX, Inc. is a national medical group that comprises the nation's leading providers of neonatal, anesthesia, maternal-fetal and pediatric subspecialty services. The Company is reshaping the delivery of care within its specialties and subspecialties using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a division of MEDNAX, was founded in 1979 and includes neonatal physicians who provide services at more than 360 neonatal intensive care units, and collaborate with affiliated maternal-fetal medicine, pediatric cardiology, pediatric critical care and physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation's largest provider of newborn hearing screens. American Anesthesiology, a division of MEDNAX, was established in 2007 and includes more than 2,150 anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX, through its affiliated professional corporations, employs more than 2,550 physicians in 34 states and Puerto Rico. Additional information is available at

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”, “plan”, “will”, “expect”, “estimate”, “project”, “positioned”, “strategy” and similar expressions, and are based on assumptions and assessments made by MEDNAX’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well MEDNAX’s current reports on Form 8-K, filed with the Securities and Exchange Commission.

Source: MEDNAX, Inc.

Charles Lynch, 954-384-0175, x-5692
Vice President, Strategy and Investor Relations